Hastings
Hastings
Hastings, Nebraska, United States11 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT06052267 | |
| A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) | cancer, neoplasm | Recruiting | Phase 2 | 2026-10-06 | NCT06979596 | |
| A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-10-06 | NCT06664619 | |
| Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-09-22 | NCT06712316 | |
| S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-09-17 | NCT04071457 | |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 3 | 2026-09-09 | NCT05633654 | |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-09-02 | NCT05879926 | |
| A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Tumor Virus Infections, hematologic disorder, immune system disorder, immunoproliferative disorder, infectious mononucleosis, leukocyte disorder, lymphatic system disorder, lymphoproliferative syndrome, viral infectious disease | Active, not recruiting | Phase 1 | 2026-08-11 | NCT05831111 | |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Early Stage Triple-Negative Breast Carcinoma | Recruiting | Phase 3 | 2026-08-05 | NCT05812807 | |
| Integrated Cancer Repository for Cancer Research | Abdominal Neoplasms, Adenomatous Polyps, Adnexal Diseases, Anal Cancer, Biliary Tract Neoplasms, Blood Protein Disorders, Colorectal Neoplasms, Hereditary Nonpolyposis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cronkhite-Canada syndrome, DNA repair disease, Digestive System Diseases, Digestive System Neoplasms, Duodenal Cancer, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Liver Neoplasms, Lynch syndrome, Male Urogenital Diseases, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplasms, Unknown Primary, Neoplastic Processes, Nose Neoplasms, Nutritional and Metabolic Diseases, Otorhinolaryngologic Neoplasms, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Peritoneal Diseases, Peritoneal Surface Malignancy, Pharyngeal Diseases, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Thoracic Neoplasms, Thymus Neoplasms, Thyroid Nodule, Unknown Primary Tumors, Urogenital Diseases, Urogenital Neoplasms, adenoma, anus disorder, anus neoplasm, benign urinary system neoplasm, bile duct cancer, bile duct disorder, bile duct neoplasm, biliary tract disorder, breast cancer, breast disorder, breast neoplasm, cardiovascular disorder, central nervous system cancer, classic familial adenomatous polyposis, colonic disorder, colonic neoplasm, colorectal neoplasm, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, duodenal disorder, duodenum cancer, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, esophageal cancer, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gallbladder disorder, gallbladder neoplasm, gastric cancer, gastric neoplasm, gastrointestinal stromal tumor, gonadal disorder, hematologic disorder, hemorrhagic disease, hereditary disease, hereditary neoplastic syndrome, hypopharynx cancer, immune system disorder, immunoproliferative disorder, intestinal disorder, kidney cancer, kidney disorder, laryngeal disorder, laryngeal neoplasm, larynx cancer, leukemia, lip cancer, lip disorder, liver cancer, liver disorder, lung cancer, lung disorder, lung neoplasm, lymphatic system disorder, lymphoproliferative syndrome, male reproductive organ cancer, male reproductive system disorder, malignant colon neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, malignant tumor of nasopharynx, melanocytic neoplasm, melanoma, mesothelial neoplasm, mesothelioma, metabolic disease, monoclonal gammopathy, mouth disorder, nasal cavity cancer, nasal disorder, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, nervous system disorder, neuroendocrine neoplasm, oral cavity cancer, otorhinolaryngologic disease, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, paranasal sinus cancer, paranasal sinus disorder, paranasal sinus neoplasm, penile cancer, penile disorder, penile neoplasm, peritoneal neoplasm, plasma cell neoplasm, primitive neuroectodermal tumor, prostate cancer, prostate disorder, rectal cancer, rectal disorder, rectal neoplasm, respiratory system disorder, respiratory tract neoplasm, salivary gland cancer, salivary gland disorder, sarcoma, skin disorder, skin neoplasm, small intestine cancer, stomach disorder, testicular cancer, testicular disorder, thymus cancer, thyroid gland disorder, thyroid tumor, ureter cancer, ureteral disorder, urethra neoplasm, urethral disorder, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine disorder, vaginal cancer, vaginal disorder, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2026-06-29 | NCT02012699 | |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer | Anatomic Stage IV Breast Cancer AJCC v8; Elevated CA15-3 or CEA or CA27-29; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8 | Recruiting | Not applicable | 2026-04-02 | NCT03723928 |